Filing Flows › Autolus Therapeutics (AUTL) › Q2 2026 › vs Q1 2026
Autolus Therapeutics (AUTL) Q2 2026 vs Q1 2026 (quarter over quarter)
Autolus Therapeutics's revenue rose $19.5M (+74%) from $26.2M in Q1 2026 to $45.7M in Q2 2026.
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $45.7M | $26.2M | $19.5M | +74% |
| Other income, net | $5.2M | −$11.2M | $16.4M | — |
| Net loss | $39.1M | $71.6M | −$32.5M | -45% |
| Costs & expenses | $90.0M | $97.8M | −$7.8M | -8% |
| Operating costs | $89.5M | $85.7M | $3.8M | +4% |
| Income tax | $465K | $863K | −$398K | -46% |
| Cost of revenue | $20.5M | $24.6M | −$4.1M | -17% |
| Research & development | $27.9M | $21.2M | $6.7M | +32% |
| SG&A | $41.2M | $40.0M | $1.2M | +3% |
| Operating cash sources | $39.1M | $71.6M | −$32.5M | -45% |
| Depreciation & amortization | $2.2M | $2.2M | −$48K | -2% |
| Share-based compensation | $4.6M | $3.6M | $1.0M | +29% |
| Working capital & other | $7.3M | $507K | $6.8M | 14× |
| Cash used in operations | $25.1M | $65.3M | −$40.2M | -62% |
| Net loss absorbed | $39.1M | $71.6M | −$32.5M | -45% |
Questions
How much did Autolus Therapeutics's revenue grow quarter over quarter in Q2 2026?
Autolus Therapeutics's revenue rose $19.5M (+74%) from $26.2M in Q1 2026 to $45.7M in Q2 2026.